Waystar Considers Sale Amid Market Challenges, Sources Reveal

Waystar, a prominent healthcare software provider, is reportedly considering various strategic options, including a potential sale, according to sources familiar with the matter. The company, whose software assists hospitals and doctors in managing payment processes, has engaged investment bank Evercore to guide the exploratory process. The discussions are still in early stages, and the outcome remains uncertain.

Waystar, headquartered in Lehi, Utah, and Louisville, Kentucky, has seen its market value decline to approximately $4.8 billion following a 24% decrease in its share price this year. This downturn comes amid a broader selloff in the software sector, raising questions about investor interest in software companies. Sources indicate that an auction process might be initiated to test market appetite for such businesses.

Strategic Focus on Technology

Since its inception from the 2017 merger of Zirmed and Navicure, Waystar has positioned itself as a technology-driven entity, focusing on automating and managing administrative tasks. This approach was designed to attract higher valuations typical of technology companies rather than those reliant on human services. Initially, investors responded positively to this strategy, with Waystar's share price peaking at $45 in 2025, up from $20.

However, concerns about potential disruptions from advancements in artificial intelligence have pressured the stock, as noted by Morgan Stanley analysts in a July report. These challenges have prompted Waystar to reassess its position in the market and explore new strategic paths, including the possibility of returning to private ownership just two years after its public debut.

Backing and Market Performance

Waystar's major shareholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and BlackRock Institutional Trust Company. EQT holds the largest stake at 13%, followed by CPPIB with 10% and BlackRock with 8%, according to data from LSEG. Despite the current market challenges, these stakeholders remain key to any potential transaction.

The company's decision to explore a sale comes at a time when the software sector faces significant headwinds, impacting valuations across the board. The outcome of Waystar's strategic review will likely depend on market conditions and investor sentiment towards technology-driven healthcare solutions.

Waystar, EQT, CPPIB, and BlackRock have declined to comment on the ongoing situation. Evercore, the investment bank advising Waystar, has yet to respond to requests for comment.